Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...

AstraZeneca PLC (LSE/STO/NASDAQ:LON:AZN), a pharmaceutical giant with a market capitalization of $215.44 billion and impressive gross profit margins of 82.61%, has received a recommendation for ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

AIM ImmunoTech (AIM) announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM’s ...

Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...

Immunotherapy has shown a 27% reduction in mortality for patients with limited-stage small cell lung cancer, based on Phase ...

Following a lung cancer diagnosis, I learned that it is important to ask oncologists thoughtful questions to know if they are ...

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...